The effects of sex steroid replacement therapy on an expanded panel of IGF-related peptides

Growth Hormone and IGF Research

Volumn 17, Issue 3, 2007, Pages 210-219

  Renehan, Andrew G ^a   Frystyk, Jan ^b   Howell, Anthony ^c   O'Dwyer, Sarah T ^a   Shalet, Stephen M ^c   Flyvbjerg, Allan ^b  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b AARHUS UNIVERSITY HOSPITAL   (Denmark)

^c CHRISTIE HOSPITAL   (United Kingdom)

Author keywords

Binding proteins; Cancer risk; Estrogen; Free IGF I; Insulin like growth factors; Progestin

Indexed keywords

CONJUGATED ESTROGEN; ESTRADIOL; ESTRADIOL VALERATE; ESTRADIOL VALERATE PLUS NORGESTREL; ESTRIOL; ESTROGEN; ESTRONE; GESTAGEN; HORMONIN; INSULIN; KLIOFEM; PREMIQUE; PREMPAK; SEX HORMONE; SOMATOMEDIN B; SOMATOMEDIN BINDING PROTEIN 2; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C; TIBOLONE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CHRONIC DISEASE; COMBINATION CHEMOTHERAPY; COMPLEX FORMATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORRELATION ANALYSIS; DIET RESTRICTION; DISEASE PREDISPOSITION; ESTROGEN THERAPY; FEMALE; HORMONE SUBSTITUTION; HUMAN; HUMAN EXPERIMENT; INSULIN BLOOD LEVEL; LINEAR SYSTEM; MONOTHERAPY; NORMAL HUMAN; OPEN STUDY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REGULATORY MECHANISM; STATISTICAL SIGNIFICANCE; ULTRAFILTRATION;

DISEASE; DISEASE SUSCEPTIBILITY; DRUG THERAPY, COMBINATION; ESTROGEN REPLACEMENT THERAPY; ESTROGENS; FEMALE; GONADAL STEROID HORMONES; HORMONE REPLACEMENT THERAPY; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEINS; MIDDLE AGED; PEPTIDES; PROGESTINS; SOMATOMEDINS;

EID: 34249978763     PISSN: 10966374     EISSN: 15322238     Source Type: Journal    
DOI: 10.1016/j.ghir.2007.01.017     Document Type: Article

References (50)

1. Leung K.C., Johannsson G., Leong G.M., and Ho K.K. Estrogen regulation of growth hormone action. Endocr. Rev. 25 (2004) 693-721
2. Kelly J.J., Rajkovic I.A., O'Sullivan A.J., Sernia C., and Ho K.K. Effects of different oral oestrogen formulations on insulin-like growth factor-I, growth hormone and growth hormone binding protein in post-menopausal women. Clin. Endocrinol. (Oxf). 39 (1993) 561-567
3. Bellantoni M.F., Vittone J., Campfield A.T., Bass K.M., Harman S.M., and Blackman M.R. Effects of oral versus transdermal estrogen on the growth hormone/insulin-like growth factor I axis in younger and older postmenopausal women: A clinical research center study. J. Clin. Endocrinol. Metab. 81 (1996) 2848-2853
4. Helle S.I., Omsjo I.H., Hughes S.C., Botta L., Huls G., Holly J.M., and Lonning P.E. Effects of oral and transdermal oestrogen replacement therapy on plasma levels of insulin-like growth factors and IGF binding proteins 1 and 3: a cross-over study. Clin. Endocrinol. (Oxf). 45 (1996) 727-732
5. O'Sullivan A.J., and Ho K.K. A comparison of the effects of oral and transdermal estrogen replacement on insulin sensitivity in postmenopausal women. J. Clin. Endocrinol. Metab. 80 (1995) 1783-1788
6. Cano A., Castelo-Branco C., and Tarin J.J. Effect of menopause and different combined estradiol-progestin regimens on basal and growth hormone-releasing hormone-stimulated serum growth hormone, insulin-like growth factor-1, insulin-like growth factor binding protein (IGFBP)-1, and IGFBP-3 levels. Fertil. Steril. 71 (1999) 261-267
7. Kam G.Y., Leung K.C., Baxter R.C., and Ho K.K. Estrogens exert route- and dose-dependent effects on insulin-like growth factor (IGF)-binding protein-3 and the acid-labile subunit of the IGF ternary complex. J. Clin. Endocrinol. Metab. 85 (2000) 1918-1922
8. Cardim H.J., Lopes C.M., Giannella-Neto D., da Fonseca A.M., and Pinotti J.A. The insulin-like growth factor-I system and hormone replacement therapy. Fertil. Steril. 75 (2001) 282-287
9. Heald A., Selby P.L., White A., and Gibson J.M. Progestins abrogate estrogen-induced changes in the insulin-like growth factor axis. Am. J. Obstet. Gynecol. 183 (2000) 593-600
10. Nugent A.G., Leung K.C., Sullivan D., Reutens A.T., and Ho K.K. Modulation by progestogens of the effects of oestrogen on hepatic endocrine function in postmenopausal women. Clin. Endocrinol. (Oxf). 59 (2003) 690-698
11. Goodman-Gruen D., and Barrett-Connor E. Effect of replacement estrogen on insulin-like growth factor-I in postmenopausal women: The Rancho Bernardo Study. J. Clin. Endocrinol. Metab. 81 (1996) 4268-4271
12. Vestergaard P., Hermann A.P., Orskov H., and Mosekilde L. Effect of sex hormone replacement on the insulin-like growth factor system and bone mineral: A cross-sectional and longitudinal study in 595 perimenopausal women participating in the Danish Osteoporosis Prevention Study. J. Clin. Endocrinol. Metab. 84 (1999) 2286-2290
13. Holmes M.D., Pollak M.N., and Hankinson S.E. Lifestyle correlates of plasma insulin-like growth factor I and insulin-like growth factor binding protein 3 concentrations. Cancer Epidemiol. Biomarkers Prev. 11 (2002) 862-867
14. Morimoto L.M., Newcomb P.A., White E., Bigler J., and Potter J.D. Variation in plasma insulin-like growth factor-1 and insulin-like growth factor binding protein-3: Personal and lifestyle factors (United States). Cancer Cause. Control 16 (2005) 917-927
15. Gram I.T., Norat T., Rinaldi S., Dossus L., Lukanova A., Tehard B., Clavel-Chapelon F., van Gils C.H., van Noord P.A., Peeters P.H., Bueno-de-Mesquita H.B., Nagel G., Linseisen J., Lahmann P.H., Boeing H., Palli D., Sacerdote C., Panico S., Tumino R., Sieri S., Dorronsoro M., Quiros J.R., Navarro C.A., Barricarte A., Tormo M.J., Gonzalez C.A., Overvad K., Paaske Johnsen S., Olsen A., Tjonneland A., Travis R., Allen N., Bingham S., Khaw K.T., Stattin P., Trichopoulou A., Kalapothaki V., Psaltopoulou T., Casagrande C., Riboli E., and Kaaks R. Body mass index, waist circumference and waist-hip ratio and serum levels of IGF-I and IGFBP-3 in European women. Int. J. Obes. 21 (2006) 21
16. Kim J.G., and Lee J.Y. Changes in profiles of circulating insulin-like growth factor components during hormone replacement therapy according to the responsiveness to therapy in postmenopausal women. Am. J. Obstet. Gynecol. 184 (2001) 1139-1144
17. Aiello E.J., Tworoger S.S., Yasui Y., Stanczyk F.Z., Potter J., Ulrich C.M., Irwin M., and McTiernan A. Associations among circulating sex hormones, insulin-like growth factor, lipids, and mammographic density in postmenopausal women. Cancer Epidemiol. Biomarkers Prev. 14 (2005) 1411-1417
18. Heald A., Kaushal K., Anderson S., Redpath M., Durrington P.N., Selby P.L., and Gibson M.J. Effects of hormone replacement therapy on insulin-like growth factor (IGF)-I, IGF-II and IGF binding protein (IGFBP)-1 to IGFBP-4: Implications for cardiovascular risk. Gynecol. Endocrinol. 20 (2005) 176-182
19. Campagnoli C., Abba C., Ambroggio S., and Peris C. Differential effects of progestins on the circulating IGF-I system. Maturitas. 46 (2003) S39-S44
20. Renehan A.G., Zwahlen M., Minder C., O'Dwyer S.T., Shalet S.M., and Egger M. Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: Systematic review and meta-regression analysis. Lancet 363 (2004) 1346-1353
21. Renehan A.G., Harvie M., and Howell A. Insulin-like growth factor (IGF)-I, IGF binding protein-3, and breast cancer risk: Eight years on. Endocr. Relat. Cancer 13 (2006) 273-278
22. Morris J.K., George L.M., Wu T., and Wald N.J. Insulin-like growth factors and cancer: no role in screening. Evidence from the BUPA study and meta-analysis of prospective epidemiological studies. Br. J. Cancer 95 (2006) 112-117
23. Juul A., Scheike T., Davidsen M., Gyllenborg J., and Jorgensen T. Low serum insulin-like growth factor I is associated with increased risk of ischemic heart disease: A population-based case-control study. Circulation 106 (2002) 939-944
24. Gamero P., Sornay-Rendu E., and Delmas P.D. Low serum IGF-1 and occurrence of osteoporotic fractures in postmenopausal women. Lancet 355 (2000) 898-899
25. Sandhu M.S., Heald A.H., Gibson J.M., Cruickshank J.K., Dunger D.B., and Wareham N.J. Circulating concentrations of insulin-like growth factor-I and development of glucose intolerance: A prospective observational study. Lancet 359 (2002) 1740-1745
26. Flexi-Scope-Trial-Group. Single flexible sigmoidoscopy screening to prevent colorectal cancer baseline findings of a UK multicentre randomised trial. Lancet 359 (2002) 1291-1300
27. Beral V. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 362 (2003) 419-427
28. Renehan A.G., Jones J., Potten C.S., Shalet S.M., and O' Dwyer S.T. Elevated serum insulin-like growth factor (IGF)-II and IGF binding protein-2 in patients with colorectal cancer. Br. J. Cancer 83 (2000) 1344-1350
29. Renehan A.G., Atkin W.S., O'Dwyer S T., and Shalet S.M. The effect of cigarette smoking use and cessation on serum insulin-like growth factors. Br. J. Cancer 91 (2004) 1525-1531
30. Frystyk J., Skjaerbaek C., Dinesen B., and Orskov H. Free insulin-like growth factors (IGF-I and IGF-II) in human serum. FEBS Lett. 348 (1994) 185-191
31. Frystyk J., Ivarsen P., Stoving R.K., Dall R., Bek T., Hagen C., and Orskov H. Determination of free insulin-like growth factor-I in human serum: Comparison of ultrafiltration and direct immunoradiometric assay. Growth Horm. IGF Res. 11 (2001) 117-127
32. Westwood M., Gibson J.M., Williams A.C., Clayton P.E., Hamberg O., Flyvbjerg A., and White A. Hormonal regulation of circulating insulin-like growth factor-binding protein-1 phosphorylation status. J. Clin. Endocrinol. Metab. 80 (1995) 3520-3527
33. Frystyk J., Hojlund K., Rasmussen K.N., Jorgensen S.P., Wildner-Christensen M., and Orskov H. Development and clinical evaluation of a novel immunoassay for the binary complex of IGF-I and IGF-binding protein-1 in human serum. J. Clin. Endocrinol. Metab. 87 (2002) 260-266
34. McCaffery K., Wardle J., Nadel M., and Atkin W. Socioeconomic variation in participation in colorectal cancer screening. J. Med. Screen. 9 (2002) 104-108
35. Lissett C.A., and Shalet S.M. The impact of dose and route of estrogen administration on the somatotropic axis in normal women. J. Clin. Endocrinol. Metab. 88 (2003) 4668-4672
36. Chen J.W., Hojlund K., Beck-Nielsen H., Sandahl Christiansen J., Orskov H., and Frystyk J. Free rather than total circulating insulin-like growth factor-I determines the feedback on growth hormone release in normal subjects. J. Clin. Endocrinol. Metab. 90 (2005) 366-371
37. Veldhuis J.D., Anderson S.M., Kok P., Iranmanesh A., Frystyk J., Orskov H., and Keenan D.M. Estradiol supplementation modulates growth hormone (GH) secretory-burst waveform and recombinant human insulin-like growth factor-I-enforced suppression of endogenously driven GH release in postmenopausal women. J. Clin. Endocrinol. Metab. 89 (2004) 1312-1318
38. Lu X., Shi Z., and Murphy L.J. Growth hormone suppression of insulin-like growth factor binding protein-1 promoter activity. Mol. Cell Endocrinol. 149 (1999) 19-28
39. Coulson V.J., Wass J.A., Abdulla A.F., Cotterill A.M., and Holly J.M. Insulin-like growth factor binding proteins (IGFBPs) in acromegaly. Growth Regul. 1 (1991) 119-124
40. Frost V.J., Helle S.I., Lonning P.E., van der Stappen J.W., and Holly J.M. Effects of treatment with megestrol acetate, aminoglutethimide, or formestane on insulin-like growth factor (IGF) I and II, IGF-binding proteins (IGFBPs), and IGFBP-3 protease status in patients with advanced breast cancer. J. Clin. Endocrinol. Metab. 81 (1996) 2216-2221
41. Veldhuis J.D., Frystyk J., Iranmanesh A., and Orskov H. Testosterone and estradiol regulate free insulin-like growth factor I (IGF-I), IGF binding protein 1 (IGFBP-1), and dimeric IGF-I/IGFBP-1 concentrations. J. Clin. Endocrinol. Metab. 90 (2005) 2941-2947 Epub 2005 Feb 2915
42. Hoeflich A., Reisinger R., Lahm H., Kiess W., Blum W.F., Kolb H.J., Weber M.M., and Wolf E. Insulin-like growth factor-binding protein 2 in tumorigenesis: Protector or promoter?. Cancer Res. 61 (2001) 8601-8610
43. Million Women Study Collaborators. Patterns of use of hormone replacement therapy in one million women in Britain, 1996-2000. BJOG 109 (2002) 1319-1330.
44. Simon J.A., Hsia J., Cauley J.A., Richards C., Harris F., Fong J., Barrett-Connor E., and Hulley S.B. Postmenopausal hormone therapy and risk of stroke: The heart and estrogen-progestin replacement study (HERS). Circulation. 103 (2001) 638-642
45. Anderson G.L., Limacher M., Assaf A.R., Bassford T., Beresford S.A., Black H., Bonds D., Brunner R., Brzyski R., Caan B., Chlebowski R., Curb D., Gass M., Hays J., Heiss G., Hendrix S., Howard B.V., Hsia J., Hubbell A., Jackson R., Johnson K.C., Judd H., Kotchen J.M., Kuller L., LaCroix A.Z., Lane D., Langer R.D., Lasser N., Lewis C.E., Manson J., Margolis K., Ockene J., O'Sullivan M.J., Phillips L., Prentice R.L., Ritenbaugh C., Robbins J., Rossouw J.E., Sarto G., Stefanick M.L., Van Horn L., Wactawski-Wende J., Wallace R., and Wassertheil-Smoller S. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: The women's health initiative randomized controlled trial. JAMA 291 (2004) 1701-1712
46. Rossouw J.E., Anderson G.L., Prentice R.L., LaCroix A.Z., Kooperberg C., Stefanick M.L., Jackson R.D., Beresford S.A., Howard B.V., Johnson K.C., Kotchen J.M., and Ockene J. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the women's health initiative randomized controlled trial. JAMA 288 (2002) 321-333
47. Hulley S.B., and Grady D. The WHI estrogen-alone trial - do things look any better?. JAMA 291 (2004) 1769-1771
48. Lukanova A., Lundin E., Toniolo P., Micheli A., Akhmedkhanov A., Rinaldi S., Muti P., Lenner P., Biessy C., Krogh V., Zeleniuch-Jacquotte A., Berrino F., Hallmans G., Riboli E., and Kaaks R. Circulating levels of insulin-like growth factor-I and risk of ovarian cancer. Int. J. Cancer 101 (2002) 549-554
49. Lukanova A., Lundin E., Micheli A., Akhmedkhanov A., Rinaldi S., Muti P., Lenner P., Biessy C., Krogh V., Riboli E., Hallmans G., Berrino F., Zeleniuch-Jacquotte A., Toniolo P., and Kaaks R. Risk of ovarian cancer in relation to prediagnostic levels of C-peptide, insulin-like growth factor binding proteins-1 and -2 (USA, Sweden, Italy). Cancer Cause. Control 14 (2003) 285-292
50. Klotz D.M., Hewitt S.C., Ciana P., Raviscioni M., Lindzey J.K., Foley J., Maggi A., DiAugustine R.P., and Korach K.S. Requirement of estrogen receptor-alpha in insulin-like growth factor-1 (IGF-1)-induced uterine responses and in vivo evidence for IGF-1/estrogen receptor cross-talk. J. Biol. Chem. 277 (2002) 8531-8537